Southwest Research Institute

swri.org

Southwest Research Institute is an independent, nonprofit, applied research and development organization. The staff numbers nearly 2,600 professionals specializing in the creation and transfer of technology in engineering and the physical sciences. Total revenue for fiscal year 2017 was more than $528 million. SwRI headquarters occupy more than 1,200 acres in San Antonio, Texas, and provide more than 2 million square feet of laboratories, test facilities, workshops, and offices.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INTEGRAL MOLECULAR PROVIDES RAPID SAFETY TESTING OF COVID-19 ANTIBODY THERAPEUTICS WITH ITS MEMBRANE PROTEOME ARRAY TECHNOLOGY

Integral Molecular | June 12, 2020

news image

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, t...

Read More

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

news image

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More

CELL AND GENE THERAPY

SYSMEX AND THINKCYTE HAVE ENTERED INTO AN AGREEMENT FOR JOINT DEVELOPMENT AND CAPITAL ALLIANCE

Sysmex Corporation | May 17, 2021

news image

Sysmex Corporation and ThinkCyte, Inc. announced today the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology in May 2021. The development of novel testing and diagnostic technologies of high clinical utility is being pursued to improve the precision of diagnoses and maximize treatment as healthcare becomes more accurate and personalized at an increased pace - in combination with the advancement of technology. M...

Read More

SAIBA AG SELECTS AGC BIOLOGICS TO DEVELOP AND PRODUCE COVID-19 VACCINE

AGC Biologics | June 16, 2020

news image

AGC Biologics, a global biopharmaceutical Contract Development Manufacturing Organization (CDMO), has announced it will be partnering with Saiba AG to manufacture a SARS-CoV-2 vaccine to protect against COVID-19. Saiba AG is a Swiss biotechnology company that specializes in the research and development of virus-like particle (VLP) vaccines for infectious and chronic diseases. Saiba AG is leveraging its patented Cucumber Mosaic Virus VLP platform technology to develop the SARS-CoV-2 vaccine. ...

Read More
news image

INTEGRAL MOLECULAR PROVIDES RAPID SAFETY TESTING OF COVID-19 ANTIBODY THERAPEUTICS WITH ITS MEMBRANE PROTEOME ARRAY TECHNOLOGY

Integral Molecular | June 12, 2020

Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.Researchers from Abound Bio and collaborators used the MPA to profile a promising monoclonal antibody that targets and neutralizes SARS-CoV-2 virus with high potency by blocking its binding to the ACE2 protein, t...

Read More
news image

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More
news image

CELL AND GENE THERAPY

SYSMEX AND THINKCYTE HAVE ENTERED INTO AN AGREEMENT FOR JOINT DEVELOPMENT AND CAPITAL ALLIANCE

Sysmex Corporation | May 17, 2021

Sysmex Corporation and ThinkCyte, Inc. announced today the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology in May 2021. The development of novel testing and diagnostic technologies of high clinical utility is being pursued to improve the precision of diagnoses and maximize treatment as healthcare becomes more accurate and personalized at an increased pace - in combination with the advancement of technology. M...

Read More
news image

SAIBA AG SELECTS AGC BIOLOGICS TO DEVELOP AND PRODUCE COVID-19 VACCINE

AGC Biologics | June 16, 2020

AGC Biologics, a global biopharmaceutical Contract Development Manufacturing Organization (CDMO), has announced it will be partnering with Saiba AG to manufacture a SARS-CoV-2 vaccine to protect against COVID-19. Saiba AG is a Swiss biotechnology company that specializes in the research and development of virus-like particle (VLP) vaccines for infectious and chronic diseases. Saiba AG is leveraging its patented Cucumber Mosaic Virus VLP platform technology to develop the SARS-CoV-2 vaccine. ...

Read More